AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEUREN PICKS NEW COMPOUND FOR ORAL TREATMENT OF PARKINSONS.
(Full text of this release can be found at http: www.asianetnews.net)
SYDNEY, August 2/MediaNet International-AsiaNet/ --
Key points:
* NNZ-2591 has shown preclinical efficacy in animal models of Parkinsons disease
* NNZ-2591 showed long term beneficial effects in Parkinsons disease, in addition to short term symptomatic relief
* NNZ-2591 was shown to be orally neuroprotective and safe in animals at over 15 times the effective dose
* NNZ-2591 is a member of a new class of Neuren compounds and has been selected for development through to human clinical trials
Neuren Pharmaceuticals (ASX: NEU) announces a new lead candidate, NNZ-2591, from its diketopiperazine (DKP) family, which has shown efficacy in a preclinical model of Parkinsons disease (PD) and in other…
- Depression in Parkinsons Disease Has both Psychological and Pathological Causes.
- Press release article from: Business Wire August 31, 2006 700+ words
...Datamonitor report "Pipeline Insight: Parkinsons Disease And Restless Legs Syndrome - Reformulations...treatments capable of curing either Parkinsons disease or Restless Legs Syndrome. Although...forecast to achieve sales of $519m for Parkinsons disease and $399m for Restless Legs ...
- Newron Pharmaceuticals' Safinamide significantly improved motor function in...
- News wire article from: Chemical Business Newsbase February 3, 2009 700+ words
...ON time in mid- to late-stage Parkinsons disease patients with motor fluctuations...patients in mid-to-late stages of Parkinsons disease, increases daily ON time of motor...patients with mid- to late-stage Parkinsons disease receiving optimized treatment with...
- Stakeholder Insight: Parkinsons Disease - Evidence of Neuroprotection Essential...
- Press release article from: M2 Presswire February 5, 2008 700+ words
...and Markets: Stakeholder Insight: Parkinsons Disease - Evidence of Neuroprotection Essential...addition of Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential...treatment dynamics to their offering Parkinsons disease (PD) is a progressive, degenerative...
- Phytopharm plc release: Commencement of clinical study of Cogane in patients...
- News wire article from: Chemical Business Newsbase April 20, 2009 700+ words
...healthy volunteers and patients with Parkinsons disease (PD). This follows approval from...the area of the brain involved in Parkinsons disease by inducing the bodys own production...the area of the brain involved in Parkinsons disease has shown substantial beneficial...
- Acadia Pharmaceuticals and Biovail announce completion of enrolment in first...
- News wire article from: Chemical Business Newsbase May 6, 2009 700+ words
...of pimavanserin in patients with Parkinsons disease psychosis (PDP). Top-line results...and is measured using the Unified Parkinsons Disease Rating Scale, or UPDRS (Parts II...III development as a treatment for Parkinsons disease psychosis. Acadia Pharmaceuticals...
- Health: Parkinsons disease will double by 2030.
- News wire article from: PPI - Pakistan Press International April 11, 2009 700+ words
...April 10 (PPI):The number of people in the world with Parkinsons disease will double by 2030, according to Dr Sarwar Siddiqui...psychological support to control it. To raise awareness about Parkinsons disease and its management, and to share new information available...
- The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years,...
- Press release article from: M2 Presswire October 22, 2007 700+ words
...PRESSWIRE-22 October 2007-Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years...announced the addition of "Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management...
- NEUREN PHARMACEUTICALS SELECTS NNZ2591 COMPOUND TO TREAT PARKINSONS DISEASE.
- Magazine article from: Ozequities News Bites August 2, 2006 700+ words
...Parkinsons and related neurological diseases. In the Parkinsons disease model, NNZ2591 was administered after onset of Parkinsonian...new area of brain disease, with new potential markets. Parkinsons disease is a progressive, degenerative neurological condition...
- New data on once-daily extended release pramipexole presented at 13th...
- News wire article from: Chemical Business Newsbase June 10, 2009 700+ words
...Movement Disorder Societys 13th International Congress of Parkinsons Disease and Movement Disorders (MDS) suggest that pramipexole...immediate release (IR) formulation in patients with advanced Parkinsons disease (PD). These data support the results from a previous...
- Parkinsons Disease Therapeutics to Exceed $4.6 billion revenue by 2012, says...
- Press release article from: M2 Presswire April 22, 2008 700+ words
M2 PRESSWIRE-22 April 2008-Reportbuyer: Parkinsons Disease Therapeutics to Exceed $4.6 billion revenue by 2012, says New Report(C)1994-2008 M2 COMMUNICATIONS LTD RDATE:24042008...
Source: HighBeam Research, NEUREN PICKS NEW COMPOUND FOR ORAL TREATMENT OF PARKINSONS.
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA
The AccessMyLibrary advertising network includes:
